In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.